# Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

> **NCT03308825** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 240 (actual)

## Conditions studied

- Influenza
- Flu

## Interventions

- **BIOLOGICAL:** Fluzone Quadrivalent vaccine
- **BIOLOGICAL:** Fluzone Quadrivalent vaccine
- **BIOLOGICAL:** Fluzone High-Dose vaccine

## Key facts

- **NCT ID:** NCT03308825
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-11
- **Primary completion:** 2017-11-22
- **Final completion:** 2017-11-22
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03308825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03308825, "Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03308825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*